PMID- 31524015
OWN - NLM
STAT- MEDLINE
DCOM- 20200131
LR  - 20211204
IS  - 1521-0464 (Electronic)
IS  - 1071-7544 (Print)
IS  - 1071-7544 (Linking)
VI  - 26
IP  - 1
DP  - 2019 Dec
TI  - Design and optimization of crocetin loaded PLGA nanoparticles against diabetic 
      nephropathy via suppression of inflammatory biomarkers: a formulation approach to 
      preclinical study.
PG  - 849-859
LID - 10.1080/10717544.2019.1642417 [doi]
AB  - Diabetic nephropathy (DN) is a serious complication of diabetes mellitus whose 
      expand process is linked with the fibrosis, renal hypertrophy and inflammation. 
      The current study was to formulate and optimize the nano-formulation of crocetin 
      (CT-PLGA-NPs) against Streptozotocin-induced renal nephropathy in rats. Double 
      emulsion evaporation technique was used for the preparation of CT-PLGA-NPs. 
      CT-PLGA-NPs were scrutinized for polydispersity index, size, gastric stability, 
      entrapment, drug-loading capacity and in-vitro drug release and in vivo 
      preclinical study. Single intraperitoneal injection of streptozotocin (STZ) 
      (55 mg/kg) and rats were divided into different group. Renal function and 
      metabolic parameters of urine and serum were estimated. Fibrotic protein, renal 
      pro-inflammatory cytokines and degree of renal damage expression were also 
      determined. We also estimated the fibronectin, type IV collagen and transforming 
      growth factor-beta1 for a possible mechanism of action. Crocetin supplement 
      (10 mg/kg) and CT-PLGA-NPs exhibited the accumulation of the drug in kidney and 
      liver of diabetic rats. Crocetin reduced the BGL and enhanced plasma insulin and 
      body weight. Dose dependent treatment of crocetin significantly (p < .001) 
      down-regulated the expression of renal tumor necrosis factor-alpha (TNF-alpha), 
      interleukin-6 (IL-6), interleukin (IL)-1beta (IL-1beta) and Monocyte Chemoattractant 
      Protein-1 (MCP-1). Crocetin significantly (p < .001) altered the expression of 
      fibronectin, type IV collagen, and transforming growth factor-beta1 (TGF-1beta). 
      Crocetin significantly (p < .001) down-regulated the protein kinase C activity 
      and the expression of nuclear factor kappaB (NF-kappaB) p65 activity and protein 
      production in renal tissue. On the basis of the available result, we can conclude 
      that nano-formulation of crocetin could attenuate the diabetic nephropathy via 
      antifibrotic and anti-inflammatory effect.
FAU - Yang, Xiaodong
AU  - Yang X
AD  - Department of General Medicine, Zhumadian Central Hospital , Zhumadian , China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Drug Deliv
JT  - Drug delivery
JID - 9417471
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Cytokines)
RN  - 0 (Inflammation Mediators)
RN  - 0 (trans-sodium crocetinate)
RN  - 11103-57-4 (Vitamin A)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 36-88-4 (Carotenoids)
RN  - 5W494URQ81 (Streptozocin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/chemistry/pharmacology
MH  - Biomarkers/*metabolism
MH  - Carotenoids/*administration & dosage/*chemistry
MH  - Cytokines/metabolism
MH  - Diabetes Mellitus, Experimental/chemically induced/drug therapy/metabolism
MH  - Diabetic Nephropathies/*drug therapy/metabolism
MH  - Down-Regulation/drug effects
MH  - Drug Evaluation, Preclinical
MH  - Inflammation/*drug therapy/metabolism
MH  - Inflammation Mediators/metabolism
MH  - Kidney/drug effects/metabolism
MH  - Nanoparticles/*chemistry
MH  - Polylactic Acid-Polyglycolic Acid Copolymer/*chemistry
MH  - Rats
MH  - Rats, Wistar
MH  - Signal Transduction/drug effects
MH  - Streptozocin/pharmacology
MH  - Vitamin A/analogs & derivatives
PMC - PMC6761602
OTO - NOTNLM
OT  - Crocetin
OT  - NF-kB
OT  - PLGA loaded nanoparticles
OT  - antidiabetic
OT  - antifibrotic
OT  - protein kinase C
OT  - streptozotocin
EDAT- 2019/09/17 06:00
MHDA- 2020/02/01 06:00
PMCR- 2019/09/14
CRDT- 2019/09/17 06:00
PHST- 2019/09/17 06:00 [entrez]
PHST- 2019/09/17 06:00 [pubmed]
PHST- 2020/02/01 06:00 [medline]
PHST- 2019/09/14 00:00 [pmc-release]
AID - 1642417 [pii]
AID - 10.1080/10717544.2019.1642417 [doi]
PST - ppublish
SO  - Drug Deliv. 2019 Dec;26(1):849-859. doi: 10.1080/10717544.2019.1642417.